Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1971 Nov 27;4(5786):529–532. doi: 10.1136/bmj.4.5786.529

Lymphocyte Response Depressive Factor in Multiple Sclerosis

E J Field, E A Caspary
PMCID: PMC1799818  PMID: 5128207

Abstract

Normal serum contains a lymphocyte response depressive factor and this is more active against the lymphocytes of the blood from which the serum was obtained than against lymphocytes from a different normal blood. The suppressive factor is thus “tailor-made” to its own lymphocytes though cross-reactivity with other lymphocytes does occur. The significance of this is discussed. The suppressive factor has a higher titre in serum from patients with multiple sclerosis or other destructive neurological disease than in normal serum. This may be an instance of a general phenomenon in which lymphocyte sensitization is ordinarily accompanied by production of a suppressor factor able to damp down response so that this is controlled by an “acceleratorbrake” mechanism. The possibilities of imbalance in the pathogenesis of disease and therapeutic manipulation of the level of suppressor substance are briefly discussed.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloom B. R. In vitro methods in cell-mediated immunity in man. N Engl J Med. 1971 May 27;284(21):1212–1213. doi: 10.1056/NEJM197105272842111. [DOI] [PubMed] [Google Scholar]
  2. CASPARY E. A., FIELD E. J. AN ENCEPHALITOGENIC PROTEIN OF HUMAN ORIGIN: SOME CHEMICAL AND BIOLOGICAL PROPERTIES. Ann N Y Acad Sci. 1965 Mar 31;122:182–198. doi: 10.1111/j.1749-6632.1965.tb20202.x. [DOI] [PubMed] [Google Scholar]
  3. Canales L., Middlemas R. O., 3rd, Louro J. M., South M. A. Immunological observations in chronic mucocutaneous candidiasis. Lancet. 1969 Sep 13;2(7620):567–571. doi: 10.1016/s0140-6736(69)90264-5. [DOI] [PubMed] [Google Scholar]
  4. Caspary E. A., Field E. J. Lymphocyte sensitization in sarcoidosis. Br Med J. 1971 Apr 17;2(5754):143–145. doi: 10.1136/bmj.2.5754.143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Caspary E. A., Field E. J. Sensitization of blood lymphocytes to possible antigens in neurological disease. Eur Neurol. 1970;4(5):257–266. doi: 10.1159/000114027. [DOI] [PubMed] [Google Scholar]
  6. Caspary E. A., Field E. J. Specific lymphocyte sensitization in cancer: is there a common antigen in human malignant neoplasia? Br Med J. 1971 Jun 12;2(5762):613–617. doi: 10.1136/bmj.2.5762.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cooperband S. R., Bondevik H., Schmid K., Mannick J. A. Transformation of human lymphocytes: inhibition by homologous alpha globulin. Science. 1968 Mar 15;159(3820):1243–1244. doi: 10.1126/science.159.3820.1243. [DOI] [PubMed] [Google Scholar]
  8. FIELD E. J., CASPARY E. A., BALL E. J. Some biological properties of a highly active encephalitogenic factor isolated from human brain. Lancet. 1963 Jul 6;2(7297):11–13. doi: 10.1016/s0140-6736(63)92533-9. [DOI] [PubMed] [Google Scholar]
  9. Field E. J., Caspary E. A. Demonstration of sensitized lymphocytes in blood. J Clin Pathol. 1971 Mar;24(2):179–181. doi: 10.1136/jcp.24.2.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Field E. J., Caspary E. A. Is maternal lymphocyte sensitisation passed to the child? Lancet. 1971 Aug 14;2(7720):337–342. doi: 10.1016/s0140-6736(71)90059-6. [DOI] [PubMed] [Google Scholar]
  11. Heilman D. H., McFarland W. Inhibition of tuberculin-induced mitogenesis in cultures of lymphocytes from tuberculous donors. Int Arch Allergy Appl Immunol. 1966;30(1):58–66. doi: 10.1159/000229793. [DOI] [PubMed] [Google Scholar]
  12. Hughes D., Caspary E. A., Field E. J. Lymphocyte trnsformation induced by encephalitogenic factor in multiple sclerosis and other neurological diseases. Lancet. 1968 Dec 7;2(7580):1205–1207. doi: 10.1016/s0140-6736(68)91690-5. [DOI] [PubMed] [Google Scholar]
  13. Knowles M., Hughes D., Caspary E. A., Field E. J. Lymphocyte transformation in multiple sclerosis. Inhibition of unstimulated thymidine uptake by a serum factor. Lancet. 1968 Dec 7;2(7580):1207–1209. doi: 10.1016/s0140-6736(68)91691-7. [DOI] [PubMed] [Google Scholar]
  14. Levene G. M., Turk J. L., Wright D. J., Grimble A. G. Reduced lymphocyte transformation due to a plasma factor in patients with active syphilis. Lancet. 1969 Aug 2;2(7614):246–247. doi: 10.1016/s0140-6736(69)90010-5. [DOI] [PubMed] [Google Scholar]
  15. Mackler B. F. Role of soluble lymphocyte mediators in malignant-tumour destruction. Lancet. 1971 Aug 7;2(7719):297–301. doi: 10.1016/s0140-6736(71)91338-9. [DOI] [PubMed] [Google Scholar]
  16. McFarlin D. E., Oppenheim J. J. Impaired lymphocyte transformation in ataxia-telangiectasia in part due to a plasma inhibitory factor. J Immunol. 1969 Dec;103(6):1212–1222. [PubMed] [Google Scholar]
  17. Paronetto F., Popper H. Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane. N Engl J Med. 1970 Aug 6;283(6):277–280. doi: 10.1056/NEJM197008062830602. [DOI] [PubMed] [Google Scholar]
  18. Van den Noort S., Stjernholm R. L. Lymphotoxic activity in multiple sclerosis serum. Neurology. 1971 Aug;21(8):783–793. doi: 10.1212/wnl.21.8.783. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES